← Back to Search

Diagnostic Test

MRI for Prostate Cancer

N/A
Recruiting
Led By Clare Tempany-Afdhal
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Recently diagnosed with prostate cancer for whom definitive surgical treatment is indicated
Be older than 18 years old
Must not have
Prior hip replacement or other major pelvic surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at how well MRI works in finding and staging prostate cancer, which may help treatment planning.

Who is the study for?
This trial is for men recently diagnosed with prostate cancer who are candidates for definitive surgery. It's not open to those who've had previous treatments for prostate cancer, major pelvic surgeries like hip replacements, or can't have an MRI due to severe claustrophobia, certain metal implants, kidney failure, or exceeding the scanner's weight limit.
What is being tested?
The study is testing how well a type of advanced imaging called multiparametric MRI works in assessing the stage of prostate cancer and aiding in treatment planning. The goal is to see if this MRI technique can better identify aggressive types of prostate cancer.
What are the potential side effects?
Potential side effects mainly relate to undergoing an MRI scan and may include discomfort from lying still during the procedure, loud noises from the machine (ear protection is provided), and reactions to contrast agents used such as nausea or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have recently been diagnosed with prostate cancer and need surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a hip replacement or major surgery in my pelvic area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Diagnostic performance of overall prostate imaging reporting and data system (PI-RADS) score
Risk prediction model
Secondary study objectives
Diagnostic performance of the individual prostate imaging reporting and data system (PI-RADS) score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (mpMRI)Experimental Treatment1 Intervention
Patients undergo mpMRI within 3 months prior to schedule surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Multiparametric Magnetic Resonance Imaging
2021
Completed Early Phase 1
~10

Find a Location

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
121 Previous Clinical Trials
179,345 Total Patients Enrolled
2 Trials studying Prostate Cancer
683 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,111,265 Total Patients Enrolled
516 Trials studying Prostate Cancer
332,960 Patients Enrolled for Prostate Cancer
Clare Tempany-AfdhalPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Media Library

Multiparametric Magnetic Resonance Imaging (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT03697148 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top